Alexander C.J. van Akkooi
A5075441317- Cutaneous Melanoma Detection and Management
- Melanoma and MAPK Pathways
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Nonmelanoma Skin Cancer Studies
- Clusterin in disease pathology
- Immunotherapy and Immune Responses
- S100 Proteins and Annexins
- Nuclear Structure and Function
- Ferroptosis and cancer prognosis
- Polyomavirus and related diseases
- AI in cancer detection
- Cell Image Analysis Techniques
- Full-Duplex Wireless Communications
- Antenna Design and Analysis
- Optical Coherence Tomography Applications
- Cutaneous lymphoproliferative disorders research
- Virus-based gene therapy research
- Breast Cancer Treatment Studies
- Cancer Genomics and Diagnostics
- Sarcoma Diagnosis and Treatment
- Health Systems, Economic Evaluations, Quality of Life
- Viral Infectious Diseases and Gene Expression in Insects
- FOXO transcription factor regulation
- Infectious Diseases and Mycology
The University of Sydney
2022-2025
Melanoma Institute Australia
2021-2025
Royal Prince Alfred Hospital
2022-2025
The Netherlands Cancer Institute
2015-2024
Maastricht University
2024
Medisch Spectrum Twente
2024
Molecular Oncology (United States)
2024
Leiden University Medical Center
2010-2024
University Medical Center Utrecht
2024
Dutch Cancer Society
2019-2024
The programmed death 1 (PD-1) inhibitor pembrolizumab has been found to prolong progression-free and overall survival among patients with advanced melanoma. We conducted a phase 3 double-blind trial evaluate as adjuvant therapy in resected, high-risk stage III melanoma.Patients completely resected melanoma were randomly assigned (with stratification according cancer geographic region) receive 200 mg of (514 patients) or placebo (505 intravenously every weeks for total 18 doses (approximately...
Whether immune-related adverse events (irAEs) indicate drug activity in patients treated with immune checkpoint inhibitors remains unknown.To investigate the association between irAEs and recurrence-free survival (RFS) double-blind EORTC 1325/KEYNOTE-054 clinical trial comparing pembrolizumab therapy placebo for treatment of high-risk stage III melanoma.A total 1019 adults melanoma were randomly assigned on a 1:1 ratio to receive or placebo. Eligible 18 years older complete resection...
Immune checkpoint inhibitors and targeted therapies have dramatically improved outcomes in patients with advanced melanoma, but approximately half these will not a durable benefit. Phase 1-2 trials of adoptive cell therapy tumor-infiltrating lymphocytes (TILs) shown promising responses, data from phase 3 are lacking to determine the role TILs treating melanoma.In this 3, multicenter, open-label trial, we randomly assigned unresectable stage IIIC or IV melanoma 1:1 ratio receive TIL...
We conducted the phase III double-blind European Organisation for Research and Treatment of Cancer (EORTC) 1325/KEYNOTE-054 trial to evaluate pembrolizumab versus placebo in patients with resected high-risk stage melanoma. On basis 351 recurrence-free survival (RFS) events at a 1.25-year median follow-up, prolonged RFS (hazard ratio [HR], 0.57; P < .0001) compared placebo. This led approval adjuvant treatment by Medicines Agency US Food Drug Administration. Here, we report an updated...
Clinical trials have recently evaluated safety and efficacy of neoadjuvant therapy among patients with surgically resectable regional melanoma metastases. To capture informative prognostic data connected to pathological response in such trials, it is critical standardize pathologic assessment reporting tumor after this treatment.The International Neoadjuvant Melanoma Consortium meetings 2016 2017 assembled pathologists from academic centers develop consensus guidelines for examination...
BackgroundPhase 1–2 trials involving patients with resectable, macroscopic stage III melanoma have shown that neoadjuvant immunotherapy is more efficacious than adjuvant immunotherapy.MethodsIn this phase 3 trial, we randomly assigned melanoma, in a 1:1 ratio, to receive two cycles of ipilimumab plus nivolumab and then undergo surgery or 12 nivolumab. Only the group who had partial response nonresponse received subsequent treatment. The primary end point was event-free survival.ResultsA...
BACKGROUND: In the previously reported primary analyses of this phase 3 trial, 12 months adjuvant pembrolizumab resulted in significantly longer recurrence- and distant metastasis-free survival than placebo patients with resected high-risk stage III melanoma. To confirm stability these benefits, longer-term data were needed. METHODS: We randomly assigned 1019 to receive 200 mg or intravenously every weeks for a total 18 doses (approximately 1 year) had 15-, 36-, 42-month median follow-up....
Neoadjuvant ipilimumab + nivolumab has demonstrated high pathologic response rates in stage III melanoma. Patients with low intra-tumoral interferon-γ (IFN-γ) signatures are less likely to benefit. We show that domatinostat (a class I histone deacetylase inhibitor) addition anti-PD-1 anti-CTLA-4 increased the IFN-γ and reduced tumor growth our murine melanoma model, rationalizing evaluation patients. To stratify patients into cohorts, we developed a baseline signature expression algorithm,...